Astraveus’ Post

This year’s ESACT was a great snapshot of a rapidly evolving cell and gene therapy (CGT) industry. Our experts Andrea Vervoort, Keara Sutherland, and Oliver Varette highlight 3 standout conference insights: ✔ The need for viral vectors is expected to continue to grow. This necessitates efficient and economical manufacturing methods to meet rising demand while also being mindful of environmental footprints. ✔ Industry leveraging AI/ML to model and optimize manufacturing processes, predict optimal outcomes and improve efficiency. Marinna Madrid, presented an AI/ML model for the automated production of stem cells for personalized regenerative cell therapies. There is also an emphasis on curating datasets and minimizing data silos within organizations. ✔ An excellent talk by Cath Green highlighted the benefits of providing robust biomanufacturing capabilities to academics. This enables important research to reach clinical trials, which is crucial for scenarios such as pandemics. Integrating industry and academia is pivotal for accelerating innovative therapies. Ultimately, CGT manufacturing is undeniably complex, and industry and academia collaboration is the cornerstone for the CGT sector to take transformative strides. #biomanufacturing #ESACT2024 #innovation

Latest DON Therapeutics news The future of healthcare is being transformed by groundbreaking advancements in gene therapy, cell therapy, and immunotherapy. These innovative treatments are pushing the boundaries of what's possible in medicine. By harnessing the power of genetic material, living cells, and the body's immune system, we can now target the root causes of diseases with unprecedented precision. Gene therapy offers the potential to repair or replace faulty genes, addressing genetic disorders at their core. Cell therapy utilizes living cells to regenerate and repair damaged tissues and organs, opening new frontiers in treating a wide range of conditions. Immunotherapy leverages the immune system to fight cancer and other diseases, creating highly targeted treatments with fewer side effects. Together, these therapies represent a new era in personalized medicine, offering hope and healing to millions worldwide. The convergence of these technologies is set to change the landscape of healthcare, making once-unthinkable treatments a reality. More about DON Therapeutics: https://lnkd.in/eKs-9g9e We are always looking for new healthcare opportunities. Submit your opportunity: https://lnkd.in/dJfhwVvv #biotech #seriesa #seriesb #healthcare #genetherapy #celltherapy #funding

🌟 What an inspiring session this morning at #Dreamforce! 🌟 We had the privilege of hosting a groundbreaking discussion on "Revolutionizing Care with J&J’s Cell Therapy Platform," featuring insights from our very own Rajesh Singh, and Johnson & Johnson’s Advanced Therapies Product Group Leader Badri Sambamurthi. 🔬 Inside the Session: Rajesh and Badri delved into J&J’s innovative Cell & Gene Therapy platform—a true game-changer in personalized medicine. This platform leverages cutting-edge digital and AI capabilities to enhance patient experiences and significantly improve outcomes. Here’s what we heard: ➡️ Patient-Centric Approach: Johnson & Johnson’s approach emphasizes the importance of providing real-time updates to patients to ensure they are informed and supported throughout their treatment journey. ➡️ Continuous Learning: We help Johnson & Johnson implement innovative strategies to transform healthcare. That journey involves learning traditional biopharma methods, unlearning outdated practices, and relearning new ways to administer and distribute advanced therapies. ➡️ Targeted Therapies: Car-T therapies are revolutionizing care as they’re tailored for individual patients and offer personalized treatment options. This session was a testament to the power of collaboration and innovation in evolving healthcare. For Johnson & Johnson, it’s all about reimagining care and redefining living for patients. It’s exciting to see how digital advancements are paving the way for more effective and personalized treatments.

Personalized medicine is changing the game. Amazing insights from Badrinath Sambamurthi and Rajesh Singh on how technology and cross functional teams need to come together to meet patients and providers where they are to continue to deliver these life changing therapies. ICYMI this morning - recap below! #personalizedmedicine #cellandgenetherapy #DF24

Regeneron is making significant advancements in gene therapy for genetic hearing loss, providing new options that extend beyond the capabilities of traditional cochlear implants. 🦻 The company's recent work with DB-OTO, a targeted AAV gene therapy aimed at correcting mutations in the otoferlin gene, has demonstrated substantial potential. Early results from the CHORD trial are promising, with the initial patient responding to auditory stimuli within a few weeks of treatment. By six months, this individual was able to perceive sounds without needing a cochlear implant - an encouraging sign for natural hearing restoration. These developments not only mark a leap forward in treating hearing loss but also underscore the power of diligent research and collaboration within the biotech sector. As Regeneron presents their case studies at the #ASGCT meeting, it serves as a testament to our collective endeavor to advance and distribute life-altering therapies.👏 #GeneTherapy #Innovation #Biotech #Science #Regeneron

Day 2 at ISCT Europe 2024: Insights & Inspiration! The key takeaways from the first two days highlight some game-changing innovations, which are set to elevate the efficacy, safety, and potency of cell end gene therapies. Here’s what stood out: 1. Advances in automation and high-throughput screening will drive manufacturing efficiency. 2. The adoption of relevant cell models, such as induced pluripotent stem cells and organoids is crucial for precise potency assessments. 3. 3D cell cultures offer a more physiologically accurate environment for testing biologics and understanding their in vivo performance. Meanwhile early understanding of key regulatory requirements, considerations for standardization and scalability, is essential piece for ensuring a smooth pathway to commercialization and the long-term success of ATMP products. We were thrilled to see our own Maik Schot and Kate Arslan, PhD engage in lively discussions around these innovations at Poster #45 – "Advancing High-Quality Bioreactor-Scale Cell Culture Using In-Air Microfluidics." Looking forward to more inspiring conversations and breakthroughs in the day to come! #ISCTEU2024 #CellTherapy #GeneTherapy #Innovation #Networking #ISCT

Stop Macular Degeneration: Best Tips for Preventing Vision Loss Imagine slowly losing the ability to see the faces of loved ones, or the world around you gradually fading into a blur. For millions suffering from macular degeneration, this is a harsh reality. But there's hope on the horizon. Advances in biotech are bringing new treatments and even potential cures closer than ever. Innovations like gene therapy, stem cell treatments, and advanced pharmaceuticals are giving patients hope for a brighter, clearer future. As we continue to fight this degenerative condition, we invite you to be part of the solution. Evergrowth Biohealthcare Capital supports biotech companies at the forefront of research, including that of macular degeneration—companies that are pioneering life-changing treatments and helping restore vision to those in need. https://buff.ly/3N8dOGz If you're an accredited investor and wanting to learn more, click this Calendly link to schedule a free consultation call with Dr. Harvey Tran https://buff.ly/3XQnJWl You can also schedule a call by scanning the QR code above with your mobile phone. Disclaimer: This content is for informational purposes only and should not be considered financial advice. Investing in biotechnology involves risks, and investors should conduct their own research before making any investment decisions.

We had an action-packed few days at Phacilitate's #ATW2024 in sunny Miami. Cell and gene therapy (C&GT) is gearing up toward transformative strides. Here are a few key industry conversations: 💡 Improving patient access to C&GT: o  The problem: Exorbitant manufacturing costs and stringent regulations are barriers that translate to lower patient accessibility and affordability. o  Industry Response: For cell therapy, the industry is paving the road for allogeneic cell therapies compared to autologous with reduced production timelines, simplified supply chains, improved scalability and lower cost per dose as key advantages.   💡 Significant efforts towards automated manufacturing and decentralization. Integrating AI/ML and automation has immense potential to accelerate CGT development timelines while sparing unnecessary side effects and costs.   💡 CGT Manufacturing is far from standardization; success, especially for manufacturers, depends on production efficiency and differentiated value. Strategies such as the Design of Experiments (DoE) and bioprocess modelling can help inform rational design and impact of process changes.   Given that CGT manufacturing is multifaceted and complex, innovators are looking to tackle various manufacturing bottlenecks using synergistic and complementary strategies. Technologies that are broadly applicable, additive, and boost productivity have strong potential. More importantly, the conference highlighted the growing need for collaboration across industry and academia to drive innovation, streamline the CGT manufacturing process and lower COGS to ensure the accessibility of these life-saving therapies. #ATW2024 #cellandgenetherapy #bioprocessmanufacturing  

Hints of optimism with lower interest rate and its impact on Cell therapy funding.Key points from the 2024 Cell & Gene Meeting on the #Mesa about state of funding in CGT according to #TimHunt, CEO of the #AllianceforRegenerativeMedicine ✒ Investment Trends: Investments in cell and gene therapy reached $10.9 billion in the first half of 2024, surpassing 2019’s total but still below the pandemic peak. 🖋 Challenges: The sector has faced a “very challenging” few years, especially for smaller and preclinical organizations, with a lack of IPOs and venture capital funding 🌟 Optimism for Recovery: Experts see signs of recovery, with interest rate cuts potentially improving access to capital and a better environment for later-stage assets. 🌠 CAR T Therapies: Significant interest in CAR T therapies for autoimmune diseases, with promising data and substantial funding for companies in this space. In 2024 more than 20 CAR T programs have entered autoimmune trials with data readouts showing that CAR T therapies “could achieve clinical benefits across multiple autoimmune indications” Overall, Hunt sees 2024 as the “breakthrough year for cell therapies” due to major advances. This has translated into sizable fundraises this year for cell therapy companies, including #CapstanTherapeutics’ oversubscribed $175 million #SeriesB financing in March and #ArsenalBio’s $325 million #SeriesC funding round last month, he said. #Celltherapy #funding #ARM #MESA2024 #CART #Biospace

Stop Macular Degeneration: Best Tips for Preventing Vision Loss Imagine slowly losing the ability to see the faces of loved ones, or the world around you gradually fading into a blur. For millions suffering from macular degeneration, this is a harsh reality. But there's hope on the horizon. Advances in biotech are bringing new treatments and even potential cures closer than ever. Innovations like gene therapy, stem cell treatments, and advanced pharmaceuticals are giving patients hope for a brighter, clearer future. As we continue to fight this degenerative condition, we invite you to be part of the solution. Evergrowth Biohealthcare Capital supports biotech companies at the forefront of research, including that of macular degeneration—companies that are pioneering life-changing treatments and helping restore vision to those in need. https://buff.ly/3N8dOGz If you're an accredited investor and wanting to learn more, click this Calendly link to schedule a free consultation call with Dr. Harvey Tran https://buff.ly/3XQnJWl You can also schedule a call by scanning the QR code above with your mobile phone. Disclaimer: This content is for informational purposes only and should not be considered financial advice. Investing in biotechnology involves risks, and investors should conduct their own research before making any investment decisions.